Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

New research from medical students and faculty members associated with the University of Colorado School of Medicine at ...

Sleep Better Columbus is now offering FDA-cleared oral appliance therapy for patients diagnosed with mild to moderate ...

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

about 30% of hypertensive patients have sleep apnea. [6,7,8,9] The Wisconsin Sleep Cohort Study [10,11] found a linear relationship between 24 hour BP and AHI that was independent of confounding ...

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down the long-term thesis.

With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency ...

"Obstructive sleep apnea affects millions globally and is closely linked to ... IHL-42X demonstrated clinically meaningful reductions in the Apnea-Hypopnea Index (AHI) across all dose levels, with the ...

The ResMed Inc (ASX: RMD) share price is falling on Tuesday. What's going on? Let's dig deeper into things and find ...